Document Detail


Current pharmacotherapy options for labor induction.
MedLine Citation:
PMID:  22963686     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Labor induction is now reported to occur in up to 30 - 40% of obstetrical patients. There are a number of pharmacological options available to facilitate labor induction, including oxytocin and analogues of prostaglandins E1 and E2, which have particular utility when labor induction necessitates cervical ripening, as when labor induction occurs in the context of an unfavorable cervix.
AREAS COVERED: This paper reviews acceptable pharmacological options for labor induction, especially when cervical ripening is required. These options include oxytocin and a number of prostaglandin formulations using dinoprostone and misoprostol. It also covers several analyses of published clinical trials (Phase-III) describing evidence of effectiveness.
EXPERT OPINION: Oxytocin is best used when labor needs to be induced in the context of a favorable cervix. When the cervix is not favorable, cervical ripening using prostaglandins should precede labor induction. Either dinoprostone or misoprostol are superior to oxytocin alone for cervical ripening. However, judicious, careful considerations need to be made at the outset of labor induction so as to balance maternal and fetal risks, and these should be guided by institutional policies that reflect the evidence-base.
Authors:
J Seth Hawkins; Deborah A Wing
Related Documents :
23971236 - A comparison of clinical pregnancy rates and multiple gestation rates with 2 vs 3 embry...
23232536 - Assisted reproductive technologies in italy, 2005-2007: results from the italian assist...
23539876 - Obligatory versus elective single embryo transfer in in vitro fertilization. a populati...
17643876 - Mechanisms behind intrauterine device-induced luteal persistence in mares.
7102766 - Management of multifetal pregnancies: sixteen years' experience at the sloan hospital f...
21040396 - Parvovirus b19 infection in human pregnancy.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-11     Completed Date:  2013-01-21     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2005-14     Citation Subset:  IM    
Affiliation:
University of Texas Southwestern School of Medicine, Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, 5323 Harry Hines Boulevard, Dallas, TX 75390-9032, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cervical Ripening / drug effects
Dinoprostone / therapeutic use
Female
Humans
Labor, Induced / methods*
Misoprostol / therapeutic use
Nitric Oxide Donors / therapeutic use
Oxytocics / therapeutic use*
Oxytocin / therapeutic use
Pregnancy
Chemical
Reg. No./Substance:
0/Nitric Oxide Donors; 0/Oxytocics; 363-24-6/Dinoprostone; 50-56-6/Oxytocin; 59122-46-2/Misoprostol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Are the Effects of Early Pubertal Timing on the Initiation of Weekly Alcohol Use Mediated by Peers a...
Next Document:  Enhanced screening efficiency for endocrine-disrupting chemicals in milk and powdered milk using UPL...